Tesamorelin

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) that stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits.

Profile · 01

Overview

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) that stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits. It is FDA-approved (as Egrifta) for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research. Phase 3 clinical trials and post-market data support its efficacy and tolerability profile. This protocol presents a once-daily subcutaneous approach using the FDA-approved 2 mg dose with a one-week tolerability titration.

At a Glance

Goal
Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation
Categories
Fat LossMetabolic HealthGH SecretagogueAnti-Aging
Synergistic
Ipamorelin · CJC-1295 · GHRP-6
Profile · 02

Protocol

FDA-approved daily dosing approach with one-week tolerability titration.

Typical daily range
1–2 mg once daily (titration from 1 mg to 2 mg after Week 1)
Start
1 mg (1000 mcg) daily for Week 1 to assess tolerability
Target
2 mg (2000 mcg) daily by Week 2+ (standard FDA-approved dose)
Frequency
Once per day (subcutaneous), preferably in the evening
Cycle Length
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Timing
Evening administration recommended to coincide with nocturnal GH release; rotate injection sites
Route
Subcutaneous
Cycle
12–26 weeks on, with medical supervision for extensions up to 52 weeks

Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose. This protocol is supported by Phase 3 clinical trial data and FDA labeling.

Dose progression

Week 1
1000 mcg (1.0 mg)
Weeks 2–12+
2000 mcg (2.0 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Tesamorelin works.

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months, as demonstrated in pooled Phase 3 trial analyses. Research also explores tesamorelin's potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines. Unlike exogenous GH, tesamorelin preserves the hypothalamic-pituitary feedback loop by stimulating endogenous GH production.

Science · 02

Effects

Observations from clinical or preclinical literature.

Significant reduction in visceral adipose tissue (measurable after 3–6 months in clinical trials)
Improved lipid profiles and potential liver fat reduction in NAFLD (under investigation)
Enhanced cognitive function in older adults (research ongoing, Nature Reviews Endocrinology)
Well-tolerated with maintained benefits during continuous use up to 52 weeks
Common injection-site reactions: mild redness, itching, pain, or bruising at injection area
Musculoskeletal symptoms: joint pain (arthralgia), muscle aches, peripheral edema (mild swelling)
Carpal tunnel symptoms: occasional tingling or numbness in extremities (dose-dependent, reversible)
IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients
Science · 03

Caution

Active malignancies (tesamorelin may accelerate growth of latent tumors)
Pregnancy (may harm fetus; contraindicated per FDA labeling)
Known hypersensitivity to tesamorelin or mannitol
Monitor IGF-1 levels periodically due to potent GH stimulation
Observe blood glucose closely in diabetic patients

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc
Supports GH/IGF-1 signaling and immune function.
Vitamin D
Supports metabolic health and may enhance GH axis function.
Magnesium
Supports enzymatic processes involved in metabolic regulation.
Omega-3 fatty acids
Support lipid profile improvements complementary to tesamorelin's metabolic effects.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects
Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits
Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility
Manage stress through mindfulness or relaxation techniques to support adherence and recovery
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Waist circumference and body composition — monitor visceral fat reduction over the protocol duration
  2. Fasting blood glucose and HbA1c — track metabolic impact, especially in patients with glucose sensitivity
  3. Sleep quality and energy levels — improved GH pulsatility should correlate with better sleep and recovery
  4. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

IGF-1
Primary marker of GH stimulation; monitor to ensure levels remain within safe range.
HbA1c / Fasting Glucose
Track glycemic impact; small increases in HbA1c observed in some patients.
Lipid Panel
Monitor improvements in triglycerides, LDL, and HDL during protocol.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol swabs; allow to air-dry completely
Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel)
Insert needle at 90° (if adequate subcutaneous fat) or 45° (if lean)
Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing
Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy
Dispose of used syringes immediately in a puncture-proof sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle
Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients
Document daily dose and site rotation to maintain consistency
Tesamorelin is a prescription medication (FDA-approved as Egrifta); any off-label use should comply with applicable laws and involve qualified healthcare providers
Reference · 02

References

  1. LiverTox (NIH NIDDK)
    "Tesamorelin: Clinical and Research Information on Drug-Induced Liver Injury (2018)".
    https://www.ncbi.nlm.nih.gov/books/NBK548730/
  2. Mayo Clinic / IBM Merative
    "Tesamorelin (Subcutaneous route) Drug Information (2025)".
    https://www.mayoclinic.org/drugs-supplements/tesamorelin-subcutaneous-route/description/drg-20074632
  3. J. Clin. Endocrinol. Metab.
    Falutz J et al., "Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials (2010)".
    https://pubmed.ncbi.nlm.nih.gov/20554713/
  4. PLoS ONE
    Stanley TL et al., "Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial (2017)".
    https://pubmed.ncbi.nlm.nih.gov/28617838/
  5. Nature Reviews Endocrinology
    "Tesamorelin can improve cognitive function (Research Highlight, 2012)".
    https://www.nature.com/articles/nrendo.2012.151
  6. MedlinePlus (U.S. National Library of Medicine)
    "Tesamorelin Injection Drug Information (2025)".
    https://medlineplus.gov/druginfo/meds/a611035.html
  7. Theratechnologies, Inc.
    "EGRIFTA SV (tesamorelin) Full Prescribing Information (FDA Label, 2024)".
    https://www.theratech.com/
  8. Drugs.com
    "Tesamorelin: Uses, Dosage, Side Effects, Warnings (AHFS Monograph, 2025)".
    https://www.drugs.com/tesamorelin.html
  9. LiverTox (NIH NIDDK)
    "Tesamorelin Safety Profile (2018)".
    https://www.ncbi.nlm.nih.gov/books/NBK548730/
  10. Open RN, Chippewa Valley Technical College
    "Administration of Parenteral Medications: Nursing Skills (2023)".
    https://www.ncbi.nlm.nih.gov/books/NBK596739/
  11. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
On this page